ISR incidence decreased over time regardless of BMI group or dosing regimen, with a numerical trend toward fewer ISRs in the higher BMI group overall ( Figure 1 ).
← all excerpts
Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
1
—
—